JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online November 7, 2008, 10.2967/jnumed.108.050658
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME Activity
Right arrow All Versions of this Article:
jnumed.108.050658v1
49/12/2031    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Apolo, A. B.
Right arrow Articles by Morris, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Apolo, A. B.
Right arrow Articles by Morris, M. J.
Journal of Nuclear Medicine Vol. 49 No. 12 2031-2041
© 2008 by Society of Nuclear Medicine
doi: 10.2967/jnumed.108.050658

Continuing Education

Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer*

Andrea B. Apolo1,2, Neeta Pandit-Taskar3,4 and Michael J. Morris1,2

1 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York; 2 Department of Medicine, Weill Medical College of Cornell University, New York, New York; 3 Nuclear Medicine Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; and 4 Department of Radiology, Weill Medical College of Cornell University, New York, New York

Correspondence: For correspondence or reprints contact: Michael J. Morris, Genitourinary Oncology Service, 1275 York Ave., New York, NY 10065. E-mail: morrism{at}mskcc.org

There are presently no accurate methods of imaging prostate cancer metastases to bone. An unprecedented number of novel imaging agents, based on the biology of the disease, are now available for testing. We reviewed contemporary molecular imaging modalities that have been tested in humans with metastatic prostate cancer, with consideration of the studies' adherence to current prostate cancer clinical trial designs. Articles from the years 2002 to 2008 on PET using 18F-FDG, 11C-choline, 18F-choline, 18F-flouride, 11C-acetate, 11C-methionine, and 18F-fluoro-5{alpha}-dihydrotestosterone in patients with metastatic prostate cancer were reviewed. Although these studies are encouraging, most focus on the rising population with prostate-specific antigen, and many involve small numbers of patients and do not adhere to consensus criteria for clinical trial designs in prostate cancer. Hence, although many promising agents are available for testing, such studies would benefit from closer collaboration between those in the fields of medical oncology and nuclear medicine.

Key Words: prostate cancer • positron emission tomography • 18F-fluorodeoxyglucose • 11C-choline • 18F-fluorocholine • 11C-acetate • 11C-methionine • 18F-fluoro-5{alpha}-dihydrotestosterone

* NOTE: FOR CE CREDIT, YOU CAN ACCESS THIS ACTIVITY THROUGH THE SNM WEB SITE (http://www.snm.org/ce_online) THROUGH DECEMBER 2009.

No potential conflict of interest relevant to this article was reported.

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.